Ascorbic acid inhibits human insulin aggregation and protects against amyloid induced cytotoxicity

Archives of Biochemistry and Biophysics

Volumn 621, Issue , 2017, Pages 54-62

  Alam, Parvez ^a   Beg, Ayesha Zainab ^a   Siddiqi, Mohammad Khursheed ^a   Chaturvedi, Sumit Kumar ^a   Rajpoot, Ravi Kant ^b   Ajmal, Mohd Rehan ^a   Zaman, Masihuz ^a   Abdelhameed, Ali S ^c   Khan, Rizwan Hasan ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Amyloids; Beta sheet structure; Cell cytotoxicity; ThT binding

Indexed keywords

AMYLOID; ASCORBIC ACID; HUMAN INSULIN; INSULIN;

ABSORPTION LAG TIME; ARTICLE; CELL VIABILITY; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; FALSE POSITIVE RESULT; FLUORESCENCE SPECTROSCOPY; GABAERGIC TRANSMISSION; HUMAN; MOLECULAR DOCKING; NEUROBLASTOMA CELL LINE; PATHOPHYSIOLOGY; PHOTON CORRELATION SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN AGGREGATION; SH SY5Y CELL LINE; TRANSMISSION ELECTRON MICROSCOPY; CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; METABOLISM; NERVE CELL; PATHOLOGY; PHYSIOLOGY; SYNTHESIS;

AMYLOID; ASCORBIC ACID; CELL LINE; CELL SURVIVAL; HUMANS; INSULIN; NEURONS;

EID: 85017536005     PISSN: 00039861     EISSN: 10960384     Source Type: Journal    
DOI: 10.1016/j.abb.2017.04.005     Document Type: Article

References (55)

1. [1] Ross, C.A., Poirier, M.A., Protein aggregation and neurodegenerative disease. 2004.
2. [2] Chiti, F., Dobson, C.M., Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75 (2006), 333–366.
3. [3] Bucciantini, M., et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416 (2002), 507–511.
4. [4] El-Agnaf, O.M.A., Irvine, G.B., Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins. J. Struct. Biol. 130 (2000), 300–309.
5. [5] Fandrich, M., On the structural definition of amyloid fibrils and other polypeptide aggregates. Cell. Mol. Life Sci. 64 (2007), 2066–2078.
6. [6] Stefani, M., Biochemical and biophysical features of both oligomer/fibril and cell membrane in amyloid cytotoxicity. FEBS J. 277 (2010), 4602–4613.
7. [7] Whittingham, J.L., et al. Insulin at pH 2: structural analysis of the conditions promoting insulin fibre formation. J. Mol. Biol. 318 (2002), 479–490.
8. [8] Blundell, T.L., Dodson, G.G., Dodson, E., Hodgkin, D.C., Vijayan, M., X-ray analysis and the structure of insulin. Recent Prog. Harmon. Res. (EB Astwood, ed.), 1–40, 2013.
9. [9] Morris, A.D., et al. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. Lancet 350 (1997), 1505–1510.
10. [10] Chausmer, A.B., Zinc, insulin and diabetes. J. Am. Coll. Nutr. 17 (1998), 109–115.
11. [11] Kitagawa, K., et al. Inhibition of insulin amyloid fibril formation by cyclodextrins. Amyloid 22 (2015), 181–186.
12. [12] Jayamani, J., Shanmugam, G., Gallic acid, one of the components in many plant tissues, is a potential inhibitor for insulin amyloid fibril formation. Eur. J. Med. Chem. 85 (2014), 352–358.
13. [13] Harrison, F.E., May, J.M., Vitamin C function in the brain: vital role of the ascorbate transporter SVCT2. Free Radic. Biol. Med. 46 (2009), 719–730.
14. [14] Liang, W.-J., Johnson, D., Jarvis, S.M., Vitamin C transport systems of mammalian cells. Mol. Membr. Biol. 18 (2001), 87–95.
15. [15] Rebec, G.V., An antioxidant neuroprotectant and extracellular neuromodulator. Metals Oxidative Damage Neurol. Disord., 149, 2013.
16. [16] Sharma, S. & Ebadi, M. Antioxidants as potential therapeutics in neurodegeneration. in Systems Biology of Free Radicals and Antioxidants 2191-2273 (Springer, 2014).
17. [17] Yallampalli, S., Micci, M.-A., Taglialatela, G., Ascorbic acid prevents beta-amyloid-induced intracellular calcium increase and cell death in PC12 cells. Neurosci. Lett. 251 (1998), 105–108.
18. 2-amyloid. Brain Res. 1097 (2006), 52–58.
19. [19] Wobst, H.J., Sharma, A., Diamond, M.I., Wanker, E.E. & Bieschke, J. The green tea polyphenol (-)- epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios. FEBS Lett. 589, 77–83.
20. [20] Liao, Y.H., Chang, Y.J., Yoshiike, Y., Chang, Y.C., Chen, Y.R., Negatively charged gold nanoparticles inhibit Alzheimer's amyloidoid beta fibrillization, induce fibril dissociation, and mitigate neurotoxicity. Small 8 (2012), 3631–3639.
21. [21] Yan, J.-W., et al. Design, synthesis and evaluation of isaindigotone derivatives as dual inhibitors for acetylcholinesterase and amyloid beta aggregation. Bioorg. Med. Chem. 20 (2012), 2527–2534.
22. [22] Yatin, S.M., Varadarajan, S., Butterfield, D.A., Vitamin E prevents Alzheimer's amyloid ß-Peptide (1-42)-induced neuronal protein oxidation and reactive oxygen species production. J. Alzheimer's Dis. 2 (2000), 123–131.
23. [23] Alam, P., et al. Vitamin k3 inhibits protein aggregation: implication in the treatment of amyloid diseases. Sci. Rep., 6, 2015.
24. [24] Alam, P., Siddiqi, M.K., Chaturvedi, S.K., Zaman, M., Khan, R.H., Vitamin B12 offers neuronal cell protection by inhibiting amyloid beta-42 amyloid fibrillation. Int. J. Biol. Macromol. 99 (2017), 477–482.
25. [25] Krebs, M.R.H., Bromley, E.H.C., Donald, A.M., The binding of thioflavin-T to amyloid fibrils: localisation and implications. J. Struct. Biol. 149 (2005), 30–37.
26. [26] Bolder, S.G., Sagis, L.M.C., Venema, P., van der Linden, E., Thioflavin T and birefringence assays to determine the conversion of proteins into fibrils. Langmuir 23 (2007), 4144–4147.
27. [27] Chaturvedi, S.K., Khan, J.M., Siddiqui, M.K., Alam, P., Khan, R.H., Comparative insight into surfactants mediated amyloidogenesis of lysozyme. Int. J. Biol. Macromol. 83 (2016), 315–325.
28. [28] Ivanova, M.I., Sievers, S.A., Sawaya, M.R., Wall, J.S., Eisenberg, D., Molecular basis for insulin fibril assembly. Proc. Natl. Acad. Sci. 106 (2009), 18990–18995.
29. [29] Wang, J.-B., Wang, Y.-M., Zeng, C.-M., Quercetin inhibits amyloid fibrillation of bovine insulin and destabilizes preformed fibrils. Biochem. Biophy. Res. Commun. 415 (2011), 675–679.
30. [30] Choudhary, S., Kishore, N., Hosur, R.V., Inhibition of insulin fibrillation by osmolytes: mechanistic insights. Sci. Rep., 5, 2015.
31. [31] Marshall, K.E., et al. Hydrophobic, aromatic, and electrostatic interactions play a central role in amyloid fibril formation and stability. Biochemistry 50 (2011), 2061–2071.
32. [32] Schwabe, M., Bell, E., Bell, J., Using ANS to probe ligand induced conformational states of malate dehydrogenase. FASEB J., 30, 2016, 600.19.
33. [33] Alam, P., Rabbani, G., Badr, G., Badr, B.M., Khan, R.H., The surfactant-induced conformational and activity alterations in rhizopus niveus lipase. Cell Biochem. Biophy. 71 (2015), 1199–1206.
34. 2-induced cytotoxicity. Eur. J. Med. Chem. 121 (2015), 803–809.
35. [35] Alam, P., et al. Biophysical and molecular docking insight into the interaction of cytosine beta-D arabinofuranoside with human serum albumin. J. Luminescence 164 (2015), 123–130.
36. [36] Chaturvedi, S.K., et al. Unraveling comparative anti-amyloidogenic behavior of pyrazinamide and d-cycloserine: a mechanistic biophysical insight. PloS one 10 (2015), 1–21.
37. [37] Shinde, M.N., Barooah, N., Bhasikuttan, A.C., Mohanty, J., Inhibition and disintegration of insulin amyloid fibrils: a facile supramolecular strategy with p-sulfonatocalixarenes. Chem. Commun. 52 (2016), 2992–2995.
38. [38] Alam, P., Abdelhameed, A.S., Rajpoot, R.K., Khan, R.H., Interplay of multiple interaction forces: binding of tyrosine kinase inhibitor nintedanib with human serum albumin. J. Photochem. Photobiol. B Biol. 157 (2016), 70–76.
39. [39] Chaturvedi, S.K., Siddiqi, M.K., Alam, P., Khan, R.H., Protein misfolding and aggregation: mechanism, factors and detection. Process Biochem. 51 (2016), 1183–1192.
40. [40] Mishra, N.K., Krishna Deepak, R.N.V., Sankararamakrishnan, R., Verma, S., Controlling in vitro insulin amyloidosis with stable peptide conjugates: a combined experimental and computational study. J. Phys. Chem. B 119 (2016), 15395–15406.
41. [41] Chaturvedi, S.K., et al. Biophysical insight into the anti-amyloidogenic behavior of taurine. Int. J. Biol. Macromol. 80 (2015), 375–384.
42. [42] Tatkiewicz, W., et al. Methods for characterization of protein aggregates. Insoluble Proteins Methods Protoc. 1258 (2015), 387–401.
43. 242. J. Struct. Biol. 194 (2016), 404–414.
44. [44] Rajan, R., Matsumura, K., A zwitterionic polymer as a novel inhibitor of protein aggregation. J. Mater. Chem. B 3 (2015), 5683–5689.
45. [45] Sayre, L.M., Perry, G., Smith, M.A., Oxidative stress and neurotoxicity. Chem. Res. Toxicol. 21 (2007), 172–188.
46. [46] Jellinger, K.A., Basic mechanisms of neurodegeneration: a critical update. J. Cell. Mol. Med. 14 (2010), 457–487.
47. [47] Vojdani, A., Bazargan, M., Vojdani, E., Wright, J., New evidence for antioxidant properties of vitamin C. Cancer Detect. Prev. 24 (1999), 508–523.
48. [48] Wannamethee, S.G., Lowe, G.D.O., Rumley, A., Bruckdorfer, K.R., Whincup, P.H., Associations of vitamin C status, fruit and vegetable intakes, and markers of inflammation and hemostasis. Am. J. Clin. Nutr. 83 (2006), 567–574.
49. [49] Ajmal, M.R., Abdelhameed, A.S., Alam, P., Khan, R.H., Interaction of new kinase inhibitors cabozantinib and tofacitinib with human serum alpha-1 acid glycoprotein. A comprehensive spectroscopic and molecular Docking approach. Spectrochimica Acta Part A Mol. Biomol. Spectrosc. 159 (2016), 199–208.
50. [50] Chaturvedi, S.K., Siddiqi, M.K., Alam, P., Zaman, M., Khan, R.H., Comparative binding study of anti-tuberculosis drug pyrazinamide with serum albumins. RSC Adv. 6 (2016), 85860–85869.
51. [51] Abdelhameed, A.S., Alam, P., Khan, R.H., Binding of janus kinase inhibitor tofacitinib with human serum albumin: multi-technique approach. J. Biomol. Struct. Dyn., 1–8, 2016.
52. [52] De Genst, E., et al. A nanobody binding to non-amyloidogenic regions of the protein human lysozyme enhances partial unfolding but inhibits amyloid fibril formation. J. Phys. Chem. B 117 (2013), 13245–13258.
53. [53] Ono, K., Hirohata, M., Yamada, M., Ferulic acid destabilizes preformed Beta-amyloid fibrils in vitro. Biochem. Biophy. Res. Commun. 336 (2005), 444–449.
54. [54] Edward, J.T., Molecular volumes and the Stokes-Einstein equation. J. Chem. Educ., 47, 1970, 261.
55. [55] Khurana, R., et al. Mechanism of thioflavin T binding to amyloid fibrils. J. Struct. Biol. 151 (2005), 229–238.